However, breast tumors from aromatase inhibitor-resistant patients show high expression of SRC-1 and a reduction in disease-free survival [50]; thus, the relationship between COUP-TFII and SRC-1 expression will require further investigation. This evidence concerns the gene CYP19A1 and breast neoplasm.